UCLA Division of Hematology Oncology
Welcome,         Profile    Billing    Logout  
 0 Trials 
6 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Sanchez, Cesar Rodriguez
HER2CLIMB-05, NCT05132582 / 2021-002491-39: A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Cancer

Active, not recruiting
3
654
Europe, Canada, Japan, US, RoW
Tucatinib, TUKYSA, ONT-380, ARRY-380, Trastuzumab, Herceptin, Herceptin Hylecta, Pertuzumab, Perjeta, Combination product: Trastuzumab + Pertuzumab, Phesgo, Placebo
Seagen Inc., Merck Sharp & Dohme LLC
HER2 Positive Breast Cancer
05/25
10/27
FIRCE-1, NCT05972720: A Phase 2 Study of Firi-cel in Patients with Relapsed/refractory Large B-cell Lymphoma

Recruiting
2
123
US
Fludarabine (Conditional therapy), Cyclophosphamide Monohydrate (Conditional therapy), firi-cel (Experimental drug)
CARGO Therapeutics
Cancer, Relapsed/Refractory Large B-cell Lymphoma (LBCL)
09/25
12/26
ANTLER, NCT04637763: CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy for Relapsed/Refractory B Cell Non-Hodgkin Lymphoma

Recruiting
1
72
US, RoW
CB-010, Cyclophosphamide, Fludarabine
Caribou Biosciences, Inc.
Lymphoma, Non-Hodgkin, Relapsed Non Hodgkin Lymphoma, Refractory B-Cell Non-Hodgkin Lymphoma, Non Hodgkin Lymphoma, Lymphoma, B Cell Lymphoma, B Cell Non-Hodgkin's Lymphoma
08/25
09/25
NCT06120504: A Safety Study of SGN-35T in Adults With Advanced Cancers

Active, not recruiting
1
18
Europe, Canada, US
SGN-35T
Seagen Inc.
Lymphoma, T-Cell, Cutaneous, Hodgkin Disease, Lymphoma, T-Cell, Peripheral, Lymphoma, Large-Cell, Anaplastic, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Non-Hodgkin
06/27
04/30
NCT03763604: Named Patient Use Program to Provide Abemaciclib (LY2835219) for the Treatment of Metastatic Breast Cancer

Approved for marketing
N/A
Europe, Canada, RoW
Abemaciclib, LY2835219
Eli Lilly and Company
Metastatic Breast Cancer
 
 
Cornejo, Kim
FIRCE-1, NCT05972720: A Phase 2 Study of Firi-cel in Patients with Relapsed/refractory Large B-cell Lymphoma

Recruiting
2
123
US
Fludarabine (Conditional therapy), Cyclophosphamide Monohydrate (Conditional therapy), firi-cel (Experimental drug)
CARGO Therapeutics
Cancer, Relapsed/Refractory Large B-cell Lymphoma (LBCL)
09/25
12/26

Download Options